Today: 29 April 2026
Browse Category

Biotechnology 25 January 2026 - 6 February 2026

Illumina (ILMN) stock slides 10% after 2026 outlook puts China, research demand back in focus

Illumina (ILMN) stock slides 10% after 2026 outlook puts China, research demand back in focus

Illumina shares dropped 10.3% to $119.91 after the company forecast 2026 revenue of $4.5–$4.6 billion and non-GAAP EPS of $5.05–$5.20. Management cited progress in China but said approvals are still needed for instrument sales. Fourth-quarter revenue rose 5% to $1.16 billion, with ex-China revenue up 8%. The company expects 2026 organic revenue growth of 2–4% excluding China.
6 February 2026
···
Thermo Fisher stock price today: TMO nudges higher after Thursday drop as investors eye next week’s data

Thermo Fisher stock price today: TMO nudges higher after Thursday drop as investors eye next week’s data

Thermo Fisher shares rose 0.6% to $545.58 Friday afternoon, recovering some ground after a 4% drop Thursday. The move lagged the broader market, with the S&P 500 up 1.73%. Investors remain cautious amid weak academic research funding and uncertain lab order trends. Upcoming U.S. jobs and inflation data could affect rate expectations and valuations.
6 February 2026
··
TransCode Therapeutics stock jumps on FDA filing for Phase 2a colorectal cancer trial

TransCode Therapeutics stock jumps on FDA filing for Phase 2a colorectal cancer trial

TransCode Therapeutics shares surged nearly 19% Thursday after the company filed an amended IND application for a Phase 2a trial of TTX-MC138 in colorectal cancer patients. Trading volume hit 11.5 million shares, up from 8,500 the previous day. The dose-expansion study, set to begin in early 2026, will enroll up to 45 patients with positive ctDNA markers. The trial will run with Quantum Leap Healthcare Collaborative on the PRE-I-SPY platform.
5 February 2026
·
Amgen stock jumps 8% after earnings beat — what to know before Thursday’s open

Amgen stock jumps 8% after earnings beat — what to know before Thursday’s open

Amgen shares surged 8.2% to $366.20 Wednesday after quarterly earnings beat forecasts and the company issued a 2026 outlook above consensus. Investors focused on progress in Amgen’s MariTide obesity program, which could allow less frequent dosing. The company reported Q4 revenue of $9.9 billion and adjusted EPS of $5.29. Amgen plans $2.6 billion in 2026 capital spending and capped share buybacks at $3 billion.
5 February 2026
···
Abbott (ABT) stock price steadies after Barclays trims target; Exact Sciences vote is next key date

Abbott (ABT) stock price steadies after Barclays trims target; Exact Sciences vote is next key date

Abbott Laboratories shares edged up 0.1% to $109.43 after Barclays cut its price target to $142 but kept an Overweight rating. Nutrition sales fell 8.9% last quarter, and diagnostics dropped 2.5%. Exact Sciences shareholders will vote February 20 on Abbott’s planned $23 billion takeover. The deal is expected to close in the second quarter of 2026.
2 February 2026
···
Twist Bioscience stock jumps as record quarterly revenue lifts 2026 outlook — what investors watch next

Twist Bioscience stock jumps as record quarterly revenue lifts 2026 outlook — what investors watch next

Twist Bioscience shares surged 14% to $46.88 Monday after posting record Q1 revenue of $103.7 million and raising its full-year forecast. Gross margin reached 52%, with net loss narrowing to $30.5 million. The company reaffirmed its target to reach adjusted EBITDA breakeven by late fiscal 2026. Investors are watching if Twist can sustain margins and meet its March-quarter revenue guidance.
2 February 2026
···
Amgen stock heads into earnings week after ending Kyowa Kirin eczema pact

Amgen stock heads into earnings week after ending Kyowa Kirin eczema pact

Amgen shares fell 0.3% to $341.88 Friday after disclosing plans to end its 2021 partnership with Kyowa Kirin, which will regain global rights to the eczema drug rocatinlimab. Amgen will report fourth-quarter and full-year earnings after markets close Feb. 3, with investors focused on pipeline priorities following the Kyowa Kirin exit.
31 January 2026
····
Thermo Fisher stock slides on 2026 profit outlook as research funding cuts bite — what’s next for TMO

Thermo Fisher stock slides on 2026 profit outlook as research funding cuts bite — what’s next for TMO

Thermo Fisher shares fell 2.6% to $592.16 after the company forecast 2026 profits below Wall Street estimates, citing weaker U.S. academic research funding. The company projected adjusted earnings of $24.22 to $24.80 per share, missing consensus. Fourth-quarter revenue rose 7% to $12.21 billion, beating expectations. CFO Stephen Williamson will retire in March, with Jim Meyer named as successor.
30 January 2026
··
Denali Therapeutics stock price rises as FDA freezes rival Regenxbio’s Hunter syndrome gene therapy trials

Denali Therapeutics stock price rises as FDA freezes rival Regenxbio’s Hunter syndrome gene therapy trials

Denali Therapeutics shares rose 3.7% to $21.62 Thursday after the FDA halted Regenxbio’s gene therapy trials over a brain tumor case, intensifying focus on Denali’s Hunter syndrome drug under FDA review. Investors await Denali’s clinical data update in early February and a regulatory decision by April 5. The iShares Nasdaq Biotechnology ETF was little changed.
29 January 2026
····
Thermo Fisher (TMO) stock slides into earnings — here’s what Wall Street is watching

Thermo Fisher (TMO) stock slides into earnings — here’s what Wall Street is watching

Thermo Fisher shares fell 2.55% to $608.02 Wednesday, their second straight decline ahead of Thursday’s Q4 earnings call. Trading volume topped 2.3 million, above average, as investors weighed Danaher’s warning on weak academic research funding. The stock now sits 5.6% below its Jan. 22 high. Life-science tools stocks broadly declined during the session.
29 January 2026
···
Gilead (GILD) stock hits fresh 52-week high as new analyst targets and CEO sale filing land

Gilead (GILD) stock hits fresh 52-week high as new analyst targets and CEO sale filing land

Gilead Sciences shares closed at a 52-week high of $137.78 on Monday, up 1.36% for a fourth straight gain. CEO Daniel O’Day sold $15.6 million in stock under a pre-set plan, according to an SEC filing. BMO and UBS raised their price targets, citing momentum in HIV drugs and new coverage for Yeztugo. Trading volume exceeded normal levels as the stock outperformed major pharma peers.
27 January 2026
··
Thermo Fisher Scientific stock rises toward $631 as TMO heads into Jan. 29 earnings

Thermo Fisher Scientific stock rises toward $631 as TMO heads into Jan. 29 earnings

Thermo Fisher shares rose 0.8% to $631.24 by midday Monday in New York, rebounding from an early dip ahead of Thursday’s earnings report and 2026 outlook. Options markets point to an expected 4% swing after results. Analysts forecast Q4 earnings of $6.43 per share, up from $6.10 a year ago. The company will hold its earnings call at 8:30 a.m. ET on Jan. 29.
26 January 2026
··
Voyager Technologies stock jumps again on ISS drug-discovery deal, Wedbush call — what to watch next

Voyager Technologies stock jumps again on ISS drug-discovery deal, Wedbush call — what to watch next

Voyager Technologies shares closed up 7.4% at $37.09 Friday after announcing a contract with Space LiinTech for a microgravity drug research payload to the ISS. Wedbush initiated coverage with an Outperform rating and $46 target. Liberty Street Advisors disclosed a $17.8 million stake as of Dec. 31. Investors await updates at February conference appearances.
25 January 2026
·
ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday

ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday

ImmunityBio shares fell 12.1% to $6.45 Friday after the company previewed new data from its Phase 2 glioblastoma trial, with full results due Jan. 31. The stock traded heavily between $7.88 and $6.43. Median overall survival in the study was “not yet reached” as of Jan. 22, with 19 of 23 patients alive. Investors are watching for more details on durability, safety, and trial design.
25 January 2026
·····
1 2 3 4 … 16

Stock Market Today

  • Shanti Educational Insiders Sell ₹1.6 Billion in Stock Amid Cautious Outlook
    April 28, 2026, 8:33 PM EDT. Shanti Educational Initiatives Limited (NSE:SEIL) insiders sold shares worth ₹1.6 billion in the past year, including a significant ₹226 million sale by Jaiprakash Chiripal at prices below the current ₹200 mark. Despite a 10% share price rise recently, no insider buying was recorded, signaling possible caution among management. Insider sales in the last three months totaled ₹189 million, suggesting insiders may view shares as fully valued or overvalued. However, insiders still hold 49% of the company worth about ₹16 billion, indicating long-term commitment. Investors should note insider sales can be a weak negative signal, but these moves warrant attention alongside other fundamentals.

Latest article

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

29 April 2026
AST SpaceMobile will hold its first-quarter update call on May 11 after winning FCC approval to deploy a 248-satellite constellation for direct-to-device service. Shares fell 6.8% Tuesday, following the loss of its BlueBird 7 satellite in a failed launch. The company expects insurance to cover the loss and is targeting 45 satellites in orbit by end-2026. Investors are watching launch progress and commercial service timing.
OpenAI Target Miss Report Sends Oracle, CoreWeave and AI Stocks Lower

OpenAI Target Miss Report Sends Oracle, CoreWeave and AI Stocks Lower

29 April 2026
Oracle shares fell 4% and CoreWeave dropped 5.9% Tuesday after a Wall Street Journal report said OpenAI missed recent revenue and user targets. Nvidia, AMD, and Arm Holdings also declined, with the iShares Semiconductor ETF down 3.7%. OpenAI denied internal divisions and said its AI coding product Codex reached 4 million users. Oracle’s credit default swaps hit a two-week high amid concern over its $300 billion cloud deal with OpenAI.
Go toTop